TD Cowen Reiterates Buy Rating on Avidity Biosciences (RNA)

TD Cowen analyst Ritu Baral reiterated a Buy rating and issued a new $56 price target on Avidity Biosciences (NASDAQ: RNA).

The analyst commented, "We are optimistic for the potential of Ph3 del-desiran in DM1, which has excellent Ph1/2 clinical data and potential $1.4B in US peak sales. Excellent biomarker/fnxl data for Ph3-ready del-brax drives significant promise in FSHD; we model $1.4B in peak potential sales. RNA's pipeline gives significant PoC to their AOC platform, which drives its Ph1/2 DMD and preclin precision cardiology program."

For an analyst ratings summary and ratings history on Avidity Biosciences click here. For more ratings news on Avidity Biosciences click here.

Shares of Avidity Biosciences closed at $39.66 yesterday.

You May Also Be Interested In

• Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
• BTIG Starts Boost Run (BRUN) at Buy
• Morgan Stanley Upgrades Qualcomm (QCOM) to Equalweight